Utility of a pharmacist-managed Anticoagulation Program in patients with congenital heart disease.

Meredith J O'NeilBreAnn N GarrJenna M FairclothJulie A CiambarellaAdam M LubertNicole L NelsonDavid S Cooper

Published in: Cardiology in the young (2023)

Through a practice change incorporating a collaborative, centralized, pharmacist-managed model, this cohort of CHD patients on warfarin had a fifteen percent increase in time in therapeutic range, which was sustained for nine years.

Keyphrases

congenital heart disease
quality improvement
end stage renal disease
atrial fibrillation
venous thromboembolism
ejection fraction
newly diagnosed
chronic kidney disease
primary care
peritoneal dialysis
direct oral anticoagulants